Cite

HARVARD Citation

    Stack, A. et al. (2019). Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma. Clinical case reports. 7 (5), pp. 1003-1006. [Online]. 
  
Back to record